NCI Sharpless addresses three big issues in cancer in 2020:1. NCI grantees are prime targets for foreign influence, 2. Treatment seems to drive drop in lung cancer deaths, 3. RPG paylines to rise from 8% to 10% February 14, 2020Vol.46 No.07By Matthew Bin Han Ong
American Cancer Society CEO Gary Reedy cedes day-to-day operations to chief operating officer February 07, 2020Vol.46 No.06By Paul Goldberg
Conversation with The Cancer Letter NCI’s Penberthy: We may be seeing some impact of treatment in lung cancer mortality, but we need more data February 07, 2020Vol.46 No.06By Matthew Bin Han Ong
Conversation with The Cancer Letter ACS’s Siegel: Large drop in lung cancer mortality likely driven by treatment, not just drugs February 07, 2020Vol.46 No.06By Matthew Bin Han Ong
Are drugs really driving the latest drop in lung cancer mortality?Looks like treatment is playing a role, experts say February 07, 2020Vol.46 No.06By Matthew Bin Han Ong
Surgeon General’s report notes lack of evidence on e-cigarettes in smoking cessation January 31, 2020Vol.46 No.5By Alexandria Carolan
SU2C initiatives aim to boost diversity in cancer trials January 31, 2020Vol.46 No.5By Alexandria Carolan
Conversation with The Cancer LetterFree Thomas Lynch lists his areas of emphasis at the Hutch:Solid tumors, immuno-oncology, big data, microbial involvement January 31, 2020Vol.46 No.5By Paul Goldberg
Free The price of smoking for a lifetime is lowest in the South, highest in the NortheastHere are the numbers January 24, 2020Vol.46 No.04By Alexandria Carolan
